1-O-tert-butyl 2-O-methyl (2S,4R)-4-[4-(3-ethenylphenyl)-5-phenyltriazol-2-yl]pyrrolidine-1,2-dicarboxylate | 1163732-54-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-O-tert-butyl 2-O-methyl (2S,4R)-4-[4-(3-ethenylphenyl)-5-phenyltriazol-2-yl]pyrrolidine-1,2-dicarboxylate
• CAS: 1163732-54-4
• 化学式: C₂₇H₃₀N₄O₄
• 分子量: 474.56
• InChiKey: YWDDOOMMLOLNQZ-YADHBBJMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  86.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-O-tert-butyl 2-O-methyl (2S,4R)-4-[4-(3-ethenylphenyl)-5-phenyltriazol-2-yl]pyrrolidine-1,2-dicarboxylate 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 1.0h， 以100%的产率得到
  参考文献：
  名称：

  [EN] TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS
  [FR] INHIBITEURS MACROCYCLIQUES CONTENANT DU TRIAZOLE DES PROTÉASES À SÉRINE DU VHC

  摘要：

  本发明揭示了化合物I、II和III或其药学上可接受的盐、酯或前药，其可抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予含有本发明化合物的制药组合物来治疗受试者的HCV感染的方法。

  公开号：

  WO2009079353A1
• 作为产物：
  描述：

  1-O-tert-butyl 2-O-methyl (2S,4R)-4-[4-(3-bromophenyl)-5-phenyltriazol-2-yl]pyrrolidine-1,2-dicarboxylate 、 乙烯三氟硼酸钾 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 三乙胺 作用下， 以 乙醇 为溶剂， 反应 15.0h， 生成 1-O-tert-butyl 2-O-methyl (2S,4R)-4-[4-(3-ethenylphenyl)-5-phenyltriazol-2-yl]pyrrolidine-1,2-dicarboxylate
  参考文献：
  名称：

  [EN] TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS
  [FR] INHIBITEURS MACROCYCLIQUES CONTENANT DU TRIAZOLE DES PROTÉASES À SÉRINE DU VHC

  摘要：

  本发明揭示了化合物I、II和III或其药学上可接受的盐、酯或前药，其可抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予含有本发明化合物的制药组合物来治疗受试者的HCV感染的方法。

  公开号：

  WO2009079353A1

文献信息

• TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS
  申请人：GAI Yonghua

  公开号：US20090191151A1

  公开（公告）日：2009-07-30

  The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Gai Yonghua

  公开号：US20090238794A1

  公开（公告）日：2009-09-24

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8273709B2
  申请人：——

  公开号：US8273709B2

  公开（公告）日：2012-09-25
• US8372802B2
  申请人：——

  公开号：US8372802B2

  公开（公告）日：2013-02-12
• [EN] FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES FLUORÉS EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2009117594A1

  公开（公告）日：2009-09-24

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: ( I ) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.